Clear Search sequence regions


  • antibodies (2)
  • antigen (1)
  • antigen cd3 (1)
  • autoantigen (10)
  • b cell (6)
  • CD3 (1)
  • humans (1)
  • membranous nephropathy (2)
  • mice (2)
  • patients (2)
  • PLA2R (5)
  • scFv (1)
  • subset b cells (1)
  • synapse (1)
  • t antigen (1)
  • t lymphocytes (4)
  • therapies (1)
  • Sizes of these terms reflect their relevance to your search.

    In autoimmune diseases, autoreactive B cells comprise only the 0.1-0.5% of total circulating B cells. However, current first-line treatments rely on non-specific and general suppression of the immune system, exposing patients to severe side effects. For this reason, identification of targeted therapies for autoimmune diseases is an unmet clinical need. Here, we designed a novel class of immunotherapeutic molecules, Bi-specific AutoAntigen-T cell Engagers (BiAATEs), as a potential approach for targeting the small subset of autoreactive B cells. To test this approach, we focused on a prototype autoimmune disease of the kidney, membranous nephropathy (MN), in which phospholipase A2 receptor (PLA2R) serves as primary nephritogenic antigen. Specifically, we developed a BiAATE consisting of the immunodominant Cysteine-Rich (CysR) domain of PLA2R and the single-chain variable fragment (scFv) of an antibody against the T cell antigen CD3, connected by a small flexible linker. BiAATE creates an immunological synapse between autoreactive B cells bearing an CysR-specific surface Ig+ and T cells. Ex vivo, the BiAATE successfully induced T cell-dependent depletion of PLA2R-specific B cells isolated form MN patients, sparing normal B cells. Systemic administration of BiAATE to mice transgenic for human CD3 reduced anti-PLA2R antibody levels following active immunization with PLA2R. Should this approach be confirmed for other autoimmune diseases, BiAATEs could represent a promising off-the-shelf therapy for precision medicine in virtually all antibody-mediated autoimmune diseases for which the pathogenic autoantigen is known, leading to a paradigm shift in the treatment of these diseases. Copyright © 2024 Perico, Casiraghi, Sônego, Todeschini, Corna, Cerullo, Pezzotta, Isnard-Petit, Faravelli, Forneris, Thiam, Benigni and Remuzzi.

    Citation

    Luca Perico, Federica Casiraghi, Fabiane Sônego, Marta Todeschini, Daniela Corna, Domenico Cerullo, Anna Pezzotta, Patricia Isnard-Petit, Silvia Faravelli, Federico Forneris, Kader Thiam, Ariela Benigni, Giuseppe Remuzzi. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. Frontiers in immunology. 2024;15:1335998

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38469301

    View Full Text